Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBITDA (2024 - 2025)

Silence Therapeutics' EBITDA history spans 2 years, with the latest figure at -$3.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 120.94% year-over-year to -$3.7 million; the TTM value through Dec 2025 reached -$82.3 million, down 99.63%, while the annual FY2025 figure was -$68.2 million, 47.04% down from the prior year.
  • EBITDA for Q4 2025 was -$3.7 million at Silence Therapeutics, up from -$26.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $17.7 million in Q4 2024 and bottomed at -$30.0 million in Q3 2024.